Clinical Trial Update: A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SHR-A1811 versus Pyrotinib, each in combination with Capecitabine, for HER2-positive unresectable and/or metastatic breast cancer in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Pyrotinib (pyrotinib)
• SHR-A1811

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | Phase 3 | Status: ACTIVE_NOT_RECRUITING